Potentially inappropriate care at the end of life in patients with glioblastoma: A single-center observational cohort study.
One in 5 patients with glioblastoma received potentially inappropriate care at the end of life, predominantly through chemotherapy, and younger patients and those with methylated MGMT promoters were most affected.